[Radio-somatomedins. III. Ovarian growth factor. Its clinical use].
We label ovaric growth factor (OGF) with Iodine-131 and probed its distribution in experimental mouse with radiopharmacology, toxicology and genetical test with encouraging results. The next step was its distribution in human volunteers and ovarian cancer. The new radiopharmaco have high concentration in ovarian cancer; that make possible its scan visualization "in vivo" for diagnoses and its internal radiation treatment without collateral or adverse effects in 6 month of follow-up (clinical and laboratorial) of the volunteers and patients in where the new radiopharmaco was probed.